Iran Press/ Iran News: The world's most influential scientific journal The Lancet stated on Friday that the Russian COVID-19 vaccine generates antibodies and does not cause adverse incidents, according to preliminary results of clinical trials, reported by Telesur.
The Sputnik-V vaccine, which is given to patients in two doses, was released to the public weeks ago without providing details on its clinical trials. The Lancet study, however, presented the first findings from two clinical trials in which 76 people took part.
The researchers found that the two formulations of the vaccine - one frozen and one lyophilized - are safe as the volunteers developed antibodies after 21 days and did not present adverse reactions in over 42 days.
The results of clinical trials also show that, after a period of 28 days, the vaccines produce a response from T cells, which are the human cells responsible for detecting and eliminating invading pathogens or infected cells.
The trials were carried out in two Russian hospitals with adults aged between 18 and 60 years, who were isolated as soon as they registered to take part in clinical trials.
Scientist Alexander Gintsburg said that the third phase of the clinical trial of the Sputnik-V vaccine will include 40,000 volunteers of different age groups and with different levels of risk.
220
Read More:
Iran, Russia consult on joint production of COVID-19 vaccine
COVID-19 vaccine gets emergency use approval in China
Rouhani urges measures to prepare and test Coronavirus vaccine inside
